TCGA-46-3766-01A-01R-0980-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.660
- ALLOGRAFT_REJECTION+0.560
- ANGIOGENESIS+0.540
- IL6_JAK_STAT3_SIGNALING+0.470
- INFLAMMATORY_RESPONSE+0.470
- KRAS_SIGNALING_UP+0.470
- COMPLEMENT+0.450
- COAGULATION+0.440
- IL2_STAT5_SIGNALING+0.400
- UV_RESPONSE_DN+0.400
Top 10 suppressed
- MYC_TARGETS_V2-0.660
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.510
- MITOTIC_SPINDLE-0.370
- MYC_TARGETS_V1-0.360
- DNA_REPAIR-0.190
- SPERMATOGENESIS-0.180
- UNFOLDED_PROTEIN_RESPONSE-0.160
- OXIDATIVE_PHOSPHORYLATION-0.140
- CHOLESTEROL_HOMEOSTASIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.945 |
| 2 | TCGA-44-6777-01A-11R-1858-07 | — | cohortA1 | 0.942 |
| 3 | TCGA-CR-7386-01A-11R-2016-07 | — | — | 0.936 |
| 4 | TCGA-A7-A0CG-01A-12R-A056-07 | — | A | 0.930 |
| 5 | TCGA-05-4417-01A-22R-1858-07 | — | cohortA3 | 0.920 |
| 6 | SRR1797302 | — | cohortMD2 | 0.917 |
| 7 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.911 |
| 8 | SRR5088824 | — | — | 0.910 |
| 9 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.908 |
| 10 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.660 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.470 | Inavolisib | — uncovered |
| COMPLEMENT | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |